The Entry of Ebola into the US Has Hallmarks of a Planned Happening

The Entry of Ebola into the US Has Hallmarks of a Planned Happening

Paul Craig Roberts

More information is available that suggests the the government had advance information that ebola was coming to the US and that the government expects a much larger outbreak of the disease in the US than it admits.

Keep in mind that Washington is evil and has been killing people in seven countries for thirteen years based entirely on lies. Keep in mind that Washington has a long list of countries that it has destabilized. Most recently Washington overthrew the elected government in Ukraine and is currently working on the remaining independent governments in the Middle East, Russia, and China as Tony Cartalucci’s article documents: http://www.globalresearch.ca/turmoi...xinjiang-americas-covert-war-on-china/5409079 For six case studies of how Washington overthrows governments read The Brothers.

Here is a report from Natural News:
http://www.naturalnews.com/047118_ebola_pandemic_us_government_american_cities.html

The U.S. government knew about the outbreak in advance, but didn’t warn the public

It’s now clear that the U.S. government has long known this outbreak was coming but did nothing to warn the public.

In early September, the government sought to purchase 160,000 Ebola hazmat suits from a U.S. supplier. http://www.naturalnews.com/046884_ebola_pandemic_hazmat_suits_biological_protection.html

Furthermore, according to this report on SHTFplan.com, “Disaster Assistance Response Teams were told to prepare to be activated in the month of October.” http://www.shtfplan.com/headline-ne...o-they-would-be-activated-in-october_10012014

Don’t you find it strange that while the government itself was gearing up for an October disaster, the public wasn’t told a thing about any of this?
Paul Craig Roberts: Former Assistant Secretary of State and editor of the Wall Street Journal.

 

Oh good grief, I am beginning to realize that facts and reality simply do not matter when it comes to posting on internet discussion boards.

 

It took you this long to realize?

 

Please explain why the government has a Patent and a background for invention of this strain of the Ebola virus.

"Patents

Publication number CA2741523 A1
Publication type Application
Application number CA 2741523
PCT number PCT/US2009/062079
Publication date Apr 29, 2010
Filing date Oct 26, 2009
Priority date Oct 24, 2008
Also published as EP2350270A2, 4 More »

Inventors Jonathan S. Towner, 4 More »
Applicant Jonathan S. Towner, 5 More »
Export Citation BiBTeX, EndNote, RefMan
Classifications (21), Legal Events (1)


External Links: CIPO, Espacenet


Human ebola virus species and compositions and methods thereof
CA 2741523 A1


Abstract


Compositions and methods including and related to the Ebola Bundibugyo virus (EboBun) are provided.
Compositions are provided that are operable as immunogens to elicit and immune response or protection from EboBun challenge in a subject such as a primate. Inventive methods are directed to detection and treatment of EboBun infection.
1. An isolated hEbola virus comprising a nucleic acid molecule comprising a nucleotide sequence of:
a) a nucleotide sequence set forth in SEQ ID NOS: 1 or 10;
b) a nucleotide sequence hybridizing under stringent conditions to SEQ ID NOS:
1 or 10; or c) a nucleotide sequence of at least 70%-99% identity to the SEQ ID NOS: 1 or 10.



2. An isolated hEbola virus having Centers for Disease Control Deposit Accession No.
200706291.



3. The hEbola virus of any one of claims 1 or 2 which is killed.



4. The hEbola virus of claim 1 which is an attenuated hEbola virus.



5. The virus of claim 4 wherein at least one property of the attenuated hEbola virus is reduced from among infectivity, replication ability, protein synthesis ability, assembling ability or cytopathic effect.
6. An isolated nucleic acid molecule comprising the nucleotide sequence of SEQ
ID
NOS: 1 or 10 or a complement thereof.
7. An isolated nucleic acid molecule comprising a nucleotide sequence of between 4 and 4900 contiguous nucleotides of the nucleotide sequence of SEQ ID NOS: 1 or 10, or a complement thereof; with the proviso that said nucleotide sequence is not comprised by the nucleotide sequence set forth in SEQ ID NO: 20; or between 5500 and 6600 contiguous nucleotides of the nucleotide sequence of SEQ ID NOS: 1 or 10, or a complement thereof.
8. An isolated nucleic acid molecule comprising a nucleotide sequence that encodes the amino acid sequence of SEQ ID NO: 2-9, 59, or SEQ ID NO: 11-19 or a complement of said nucleotide sequence.
9. An isolated RNA or DNA nucleic acid molecule which hybridizes under stringent conditions to a nucleic acid molecule having the nucleotide sequence of SEQ ID
NOS: 1 or 10 or a complement thereof.
10. An isolated polypeptide encoded by the nucleic acid molecule of any one of claims 7-9.
11. An isolated polypeptide comprising the amino acid of:
a) an amino acid sequence set forth in any of SEQ ID NOS: 2-19, or 59; or b) an amino acid sequence that has 70% - 99% homology to the amino acid sequence of (a).
12. An isolated polypeptide comprising the amino acid sequence having to 250 contiguous amino acid residues of the amino acid sequence of SEQ ID
NOS: 5 or 18 (VP24);
5 to 280 contiguous residues of the amino acid sequence of SEQ ID NOS: 6 or 17 (VP30);
5 to 320 contiguous residues of the amino acid sequence of SEQ ID NOS: 8 or 13 (VP40);
5 to 340 contiguous residues of the amino acid sequence of SEQ ID NOS: 7 or 12 (VP35);
5 to 370 contiguous residues of the amino acid sequence of SEQ ID NOS: 4 or 15 (SGP);
5 to 370 contiguous residues of the amino acid sequence of SEQ ID NOS: 59 or 16 (SSGP);
5 to 670 contiguous residues of the amino acid sequence of SEQ ID NOS: 9 or 14 (GP);
5 to 730 contiguous residues of the amino acid sequence of SEQ ID NOS: 3 or 11 (NP); or 5 to 2200 contiguous residues of the amino acid sequence of SEQ ID NOS: 2 or 19 (L).
13. An isolated antibody or an antigen-binding fragment thereof which immunospecifically binds to the hEbola virus of any one of claims 1or 2 or neutralizes the virus.
14. An isolated antibody or an antigen-binding fragment thereof which immunospecifically binds to the polypeptide of any one of claims 11 or 12 or neutralizes an hEbola virus.
15. A method for detecting the presence of a the hEbola virus or a nucleic acid molecule derived therefrom of claim 1 in a biological sample, said method comprising:

(a) contacting the sample with an agent that selectively binds to the virus or the nucleic acid molecule derived therefrom; and (b) detecting whether the compound binds to the virus or the nucleic acid molecule derived therefrom in the sample.
16. The method of claim 15, wherein the agent is an antibody.
17. The method of claim 15, wherein the agent is a nucleic acid molecule comprising a nucleotide sequence having between 4 and 6600 contiguous nucleotides of the nucleotide sequence of SEQ ID NOS: 1 or 10, or a complement thereof.
18. A method for detecting the presence of the polypeptide of claim 11 in a biological sample, said method comprising:
(a) contacting the biological sample with an agent that selectively binds to said polypeptide; and (b) detecting whether the compound binds to said polypeptide in the sample.
19. The method of claim 18, wherein the agent is an antibody or an antigen-binding fragment thereof.
20. A formulation comprising the hEbola virus of any one of claims 3 or 4, and a pharmaceutically acceptable carrier.
21. A formulation comprising an amount of a protein extract of the hEbola virus of claim 3 or 4 or a subunit thereof, and a pharmaceutically acceptable carrier.
22. A formulation comprising an amount of a nucleic acid molecule of the nucleotide sequence of SEQ ID NOS: 1 or 10 or a complement thereof, and a pharmaceutically acceptable carrier.
23. A formulation comprising an immunogenically effective amount of the nucleic acid molecule of claim 9 or a complement thereof, and a pharmaceutically acceptable carrier.
24. A vaccine formulation comprising a therapeutically or prophylactically effective amount of the hEbola virus of claim 3 or 4 or a protein extract therefrom, and a pharmaceutically acceptable carrier.
25. A vaccine formulation comprising a therapeutically or prophylactically effective amount of a nucleic acid molecule SEQ ID NOS: 1 or 10 or a complement thereof, and a pharmaceutically acceptable carrier.
26. A vaccine formulation comprising a therapeutically or prophylactically effective amount of a nucleic acid molecule of claim 9 or a complement thereof, and a pharmaceutically acceptable carrier.
27. A pharmaceutical composition comprising a prophylactically or therapeutically effective amount of an anti-hEbola agent of an antibody or an antigen-binding fragment thereof which immunospecifically binds to the hEbola virus of Deposit Accession No.
200706291, or polypeptides or protein derived therefrom and optionally has the nucleotide sequence of SEQ ID
NOS: 1 or 10, or a fragment thereof.
28. A kit comprising a container containing the formulation of any one of claims 24-26.
29. A method for identifying a subject infected with the virus of claim 1 or 2, comprising:
(a) obtaining total RNA from a biological sample obtained from the subject;
(b) reverse transcribing the total RNA to obtain cDNA; and (c) amplifying the cDNA using a set of primers derived from a nucleotide sequence of the virus of claim 1 or 2.
30. A primer that has the nucleotide sequence of one of SEQ ID NOS: 24-57.
Description (OCR text may contain errors)

HUMAN EBOLA VIRUS SPECIES AND COMPOSITIONS AND METHODS THEREOF

DEPOSIT STATEMENT
[0001] The invention provides the isolated human Ebola (hEbola) viruses denoted as Bundibugyo (EboBun) deposited with the Centers for Disease Control and Prevention ("CDC";
Atlanta, Georgia, United States of America) on November 26, 2007 and accorded an accession number 200706291. This deposit was not made to an International Depository Authority (IDA) as established under the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure, and is a non-Budapest treaty deposit. The deposited organism is not acceptable by American Type Culture Collection (ATCC), Manassas, Virginia, an International Depository Authority (IDA) as established under the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. Samples of the stated Deposit Accession No. 200706291 will be made available to approved facilities for thirty years from the date of deposit, and for the lifetime of the patent issuing from, or claiming priority to this application.

RELATED APPLICATIONS

[0002] This application claims priority benefit of U.S. Provisional Application 61/108,175 filed 24 October 2008; the contents of which are hereby incorporated by reference.

FIELD OF THE INVENTION

[0003] The invention is related to compositions and methods directed to a novel species of human Ebola (hEbola) virus.

BACKGROUND OF THE INVENTION

[0004] The family Filoviridae consists of two genera, Marburgvirus and Ebolavirus, which have likely evolved from a common ancestor'. The genus Ebolavirus includes four species: Zaire, Sudan, Reston and Cote d'Ivoire (Ivory Coast) ebolaviruses, which have, with the exception of Reston and Cote d'Ivoire ebolaviruses, been associated with large hemorrhagic fever (HF) outbreaks in Africa with high case fatality (53-90%)2.
http://www.google.com/patents/CA2741523A1?cl=en

Please explain why the DOD had a lab and experimented of healthy humans in the area where this outbreak happened?
http://clinicaltrials.gov/show/NCT02041715

"
This study has suspended participant recruitment.

(This clinical trial has been suspended following a clinical hold placed on the investigational new drug TKM-100802.)

Sponsor:

Tekmira Pharmaceuticals Corporation

Collaborator:

Department of Defense

Information provided by (Responsible Party):

Tekmira Pharmaceuticals Corporation


ClinicalTrials.gov Identifier:

NCT02041715

First received: January 9, 2014

Last updated: July 31, 2014

Last verified: July 2014

History of Changes

Full Text View
Tabular View
No Study Results Posted
Disclaimer
How to Read a Study Record

Purpose


Phase 1, single-center, placebo-controlled, single-blind, first-in-human, single ascending dose (SAD) study followed by multiple ascending dose (MAD) cohorts in healthy male and female subjects.




Condition

Intervention

Phase

Ebola Virus Infection
Drug: TKM-100802 for Injection
Drug: Placebo
Phase 1







Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Official Title: A Placebo-Controlled, Single-Blind, Single-Ascending Dose Study With Additional Multiple-Ascending Dose Cohorts to Evaluate the Safety, Tolerability, and Pharmacokinetics of TKM-100802 in Healthy Human Volunteers


Resource links provided by NLM:



MedlinePlus related topics: Ebola Fever Hemorrhagic Fevers

Genetic and Rare Diseases Information Center resources: Hemorrhagic Fever Viral Hemorrhagic Fever Ebola Virus Disease
U.S. FDA Resources


Further study details as provided by Tekmira Pharmaceuticals Corporation:



Primary Outcome Measures: •Safety and tolerability of TKM-100802 [ Time Frame: 1 month ] [ Designated as safety issue: Yes ]

Subjects will be monitored for treatment-emergent and dose-limiting toxicity (DLT). If there are any adverse events (changes from baseline in laboratory parameters, vitals and/or infusion reactions) during these monitoring periods, the Independent Safety Committee, will discuss the dosing of the remaining subjects.

Before proceeding to the next dose cohort, the Independent Safety Committee will evaluate whether dose escalation will be permitted based on demonstration of adequate safety and tolerability.




Secondary Outcome Measures: •Pharmacokinetics - Cmax, Tmax and AUC [ Time Frame: 1 month ] [ Designated as safety issue: No ]
Time-points: Before infusion, mid-point of infusion, end of infusion and at 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hours after end of infusion and day 7, day 10, day 15, day 22 and day 29.








Estimated Enrollment: 28
Study Start Date: January 2014
Estimated Study Completion Date: July 2014
Estimated Primary Completion Date: July 2014 (Final data collection date for primary outcome measure) "

 

My bad I worded that badly. Unfortunately I already knew it, but it seems every day I see something that makes me continue to think we are slipping further and further away from reality and before we know it more people than not will actually believe in the nonsense that is posted on these sites. Heck we have posters here that actually post links to Blogs, other Discussion Boards and YouTube as their source of facts and truth, WT...........

 

There are good reason for it. Took a whole 30 seconds to find out why, strange you could not do the same.
http://www.newsmaxhealth.com/Headline/ebola-patent-US-government/2014/10/09/id/599636/

What’s more, the government holds patents on many microbes discovered in its labs and there is “nothing nefarious” about it,” says Sanders, who has done research into how to prevent Ebola from being used as a biological weapon.



Websites including The Common Sense Show, Natural News, and White Out Press have spread the word about the U.S. patent on Ebola, along with headlines hypothesizing that government’s intention is to “raise billions from a pandemic.” “



Sanders said that the government patents viruses and other disease-causing microbes to make sure the pathogens remain available for research purposes in the public domain. If a private company held the patents, it could potentially hold onto pathogens or charge licensing fees that would stifle research to find treatments.







“The CDC does hold some patents on life forms, but it generally does this for the common good, so a commercial company can’t come along and patent it,” Sanders told Newsmax Health.



“The CDC lets researchers work with the strain without fees,” he said.



The CDC’s patent on a strain of the Ebola virus, Ebola Bundibugyo (EboBun), was granted in 2010. The agency had applied for it a year earlier. The CDC’s genetic sequencing of the virus, which is found in Uganda, was performed in 2007, according to the patent application.


Read Latest Breaking News from Newsmax.com http://www.NewsmaxHealth.com/Headline/ebola-patent-US-government/2014/10/09/id/599636/#ixzz3GoDp0xLE
Alert: What Is Your Risk for a Heart Attack? Find Out Now

 

So you think there is any good reason for inventing a deadly virus in an African country and paying a Canadian company to infect healthy people with it and allow it to be breached into the public.
""Dr. Cyril Broderick, A Liberian scientist and a former professor of Plant Pathology at the University of Liberia’s College of Agriculture and Forestry says the West, particularly the U.S. is responsible for the Ebola outbreak in West Africa. Dr. Broderick claims the following in an exclusive article published in the Daily Observer based in Monrovia, Liberia. He wrote the following:


The US Department of Defense (DoD) is funding Ebola trials on humans, trials which started just weeks before the Ebola outbreak in Guinea and Sierra Leone. The reports continue and state that the DoD gave a contract worth $140 million dollars to Tekmira, a Canadian pharmaceutical company, to conduct Ebola research. This research work involved injecting and infusing healthy humans with the deadly Ebola virus. Hence, the DoD is listed as a collaborator in a “First in Human” Ebola clinical trial (NCT02041715, which started in January 2014 shortly before an Ebola epidemic was declared in West Africa in March."
Is there anything that you grazers wont excuse your herder for?

 

I do not think republicans are so evil that they would really do all that just to make Obama look bad..... would they?

 

what I do question though, is the cure that worked, how come not more doses of that one yet, what is holding up production?

 

You have already tried discussing your theory, has nothing to do with what I posted in reply to the question it answered. Once again you have no supporting evidence, do not try changing the subject when you cannot deal with the answers given.

 

They were not geared up to produce it, it was not a money maker before now and really will not be one now for the company, takes time to set up production and do the work, not as easy as popping out a new plastic cup or coffee machine.

 

your right of course, there is no money in a cure.. now if it was long term treatment that would bring in lot of cash, it would already be out there

something like a "vaccination" would be a money maker

sad isn't it, but that is what happens when corps control our health


.

 

Correct, The money is other "illnesses" such as erectile dysfunction and allergies.

http://www.mnwelldir.org/docs/editorial/pharm.htm

http://www.unfictional.com/big-pharma-war-on-health

http://content.healthaffairs.org/content/24/3/622.full

 

It is actually not a theory but history repeating its self.
http://www.emedicinehealth.com/biological_warfare/article_em.htm

Why are liberals so history challenged?

 

i thought he was a smart man.

now, I see he is an idiot.

 

Well yeah. That's just one of the problems with the internet. Everyone is equal, including the idiots who don't understand a thing about politics.

 

You must be thinking of the wrong doctor.
"Career

Paul Craig Roberts has had careers in scholarship and academia, journalism, public service, and business. He is chairman of The Institute for Political Economy.



Scholarship & Academia



Dr. Roberts has held academic appointments at Virginia Tech, Tulane University, University of New Mexico, Stanford University where he was Senior Research Fellow in the Hoover Institution, George Mason University where he had a joint appointment as professor of economics and professor of business administration, and Georgetown University where he held the William E. Simon Chair in Political Economy in the Center for Strategic and International Studies.

He has contributed chapters to numerous books and has published many articles in journals of scholarship, including the Journal of Political Economy, Oxford Economic Papers, Journal of Law and Economics, Studies in Banking and Finance, Journal of Monetary Economics, Public Choice, Classica et Mediaevalia, Ethics, Slavic Review, Soviet Studies, Cardoza Law Review, Rivista de Political Economica, and Zeitschrift fur Wirtschafspolitik. He has entries in the McGraw-Hill Encyclopedia of Economics and the New Palgrave Dictionary of Money and Finance.

He has contributed to Commentary, The Public Interest, The National Interest, Policy Review, National Review, The Independent Review, Harper’s, the New York Times, The Washington Post, The Los Angeles Times, Fortune, London Times, The Financial Times, TLS, The Spectator, The International Economy, Il Sole 24 Ore, Le Figaro, Liberation, and the Nihon Keizai Shimbun. He has testified before committees of Congress on 30 occasions.


Journalism



Dr. Roberts was associate editor and columnist for The Wall Street Journal and columnist for Business Week and the Scripps Howard News Service. He was a nationally syndicated columnist for Creators Syndicate in Los Angeles. In 1992 he received the Warren Brookes Award for Excellence in Journalism. In 1993 the Forbes Media Guide ranked him as one of the top seven journalists in the United States.


Public Service

President Reagan appointed Dr. Roberts Assistant Secretary of the Treasury for Economic Policy and he was confirmed in office by the U.S. Senate. From 1975 to 1978, Dr. Roberts served on the congressional staff where he drafted the Kemp-Roth bill and played a leading role in developing bipartisan support for a supply-side economic policy. After leaving the Treasury, he served as a consultant to the U.S. Department of Defense and the U.S. Department of Commerce.


Letter from Ronald Reagan to Dr. Paul Craig Roberts



Business

Dr. Roberts was president of the Inlet Beach Water Company, president of Economic & Communication Services, advisor to J.P. Morgan asset management, advisor to Tiedemann-Goodnow, advisor to Lazard Freres Asset Management, and a member of corporate and financial boards.

Books



Dr. Roberts’ latest book is How the Economy Was Lost: The War of the Worlds, published in January, 2010 by CounterPunch/AK Press. The Tyranny of Good Intentions, co-authored with IPE Fellow Lawrence Stratton, was published by Prima Publishing in May 2000. A new edition, now in a second printing, was published by Crown Publishing Group, a division of Randon House, in 2008. Chile: Two Visions—The Allende-Pinochet Era, co-authored with IPE Fellow Karen Araujo, was published in Spanish by Universidad Nacional Andres Bello in Santiago, Chile, in November 2000. The Capitalist Revolution in Latin America, co-authored with IPE Fellow Karen LaFollette Araujo, was published by Oxford University Press in 1997. A Spanish language edition was published by Oxford in 1999. The New Color Line: How Quotas and Privilege Destroy Democracy, co-authored with IPE Fellow Lawrence Stratton, was published by Regnery in 1995. A paperback edition was published in 1997. Meltdown: Inside the Soviet Economy, co-authored with IPE Fellow Karen LaFollette, was published by the Cato Institute in 1990. Harvard University Press published Roberts’ book, The Supply-Side Revolution, in 1984. Widely reviewed and favorably received, the book was praised by Forbes as “a timely masterpiece that will have real impact on economic thinking in the years ahead.” Dr. Roberts is the author of Alienation and the Soviet Economy, published in 1971 and republished in 1990. He is coauthor with Matthew Stephenson of Marx’s Theory of Exchange, Alienation and Crisis, published in 1973 by the Hoover Institution Press and republished in 1983 by Praeger Publishing. A Spanish language edition was published in 1974 in Madrid by Union Editorial..
Honors

Dr. Roberts was awarded the Treasury Department’s Meritorious Service Award for “his outstanding contributions to the formulation of United States economic policy.”

In 1987 the French government recognized him as “the artisan of a renewal in economic science and policy after half a century of state interventionism” and inducted him into the Legion of Honor.

He is listed in Who’s Who in America and Who’s Who in the World.



Tributes:




Monday, June 13, 2011

10 Most Influential People in the Alternative Media (2011)

Many readers will expect to see Matt Drudge or Arianna Huffington on this list. Although they both indeed have leading Internet news websites that cover some fringe stories and report on systematic injustices more so than the mainstream media, they primarily aggregate mainline news. Therefore, they are excluded from our “alternative media” label.
The criteria we’ve chosen to base these rankings of the most influential alternative media figures are the following;
•people that have the courage to seek the truth no matter where the information leads them;
•those with the courage to question 9/11;
•those who don’t buy into the false left-right political paradigm;
•those who are grounded in peace and liberty;
•those with the communication skills and platform to affect real change.

Significantly, each of the people who made our list is clearly driven by unyielding passion. Despite some natural disagreements, they each provide a unique bridge to forbidden knowledge and they all deserve high praise for their efforts and commitment to inform the public. Sincerely, it is very encouraging to have so many talented voices leading the stampede for truth, liberty, justice, and peace.

With so many people doing great work in the real alternative media, we are sure that some deserving reporters will be left off the list. Although Activist Post has forged relationships with some of the people on this list, we’ve tried to remain as non-biased as possible in our observations. At the end, we’ve also included a list of those who deserve honorable mention for their tireless work and talent providing the truth.
10. Dr. Paul Craig Roberts: Paul Craig Roberts is one of the most respected columnists in the alternative media. His syndicated articles can be seen on many leading alternative news websites including Lew Rockwell, Infowars, Counterpunch, InformationClearingHouse and countless others. Roberts scores huge points in the credibility department having been the former head of policy at the Department of Treasury under Reagan, and the editor of the Wall Street Journal — among a long list of other accolades. His research is impeccable and his vision of how the world really operates is second to none. He knows why and when the global chess pieces are moving, and has the incredible talent to communicate difficult concepts to the general public. He has written several books including The Tyranny of Good Intentions and How the Economy was Lost. His many interviews can be seen on Russia Today and Prison Planet TV. Roberts is also a recent contributor to Gerald Celente’s esteemed Trends Journal. There is no one better at reporting the reality of geo-political events and the workings of the Treasury and the Federal Reserve."

 

ah, so there is no evidence?

like I thought, Paul Craig Roberts is an idiot.